NervGen Pharma (NASDAQ:NGEN – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.05), Zacks reports.
NervGen Pharma Price Performance
Shares of NGEN traded up $0.06 during trading hours on Monday, reaching $1.94. 178,377 shares of the company traded hands, compared to its average volume of 514,070. The firm has a fifty day moving average price of $1.74. The stock has a market cap of $156.42 million and a P/E ratio of -4.18. NervGen Pharma has a 12 month low of $1.28 and a 12 month high of $6.30.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on NGEN shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of NervGen Pharma in a report on Monday, November 2nd. Wall Street Zen raised NervGen Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 24th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.00.
View Our Latest Report on NGEN
About NervGen Pharma
NervGen Pharma is a clinical-stage biotechnology company focused on developing treatments for nervous system injuries and diseases. The company’s research centers on ways to support nerve repair and restore function after damage to the nervous system. Its lead investigational product, NVG-291, is a peptide designed to target a protein involved in limiting nerve repair. NervGen has studied the candidate for spinal cord injury and is exploring its potential in other conditions involving nervous system damage.
Featured Articles
- Five stocks we like better than NervGen Pharma
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
